• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

VEGFR2蛋白在人HER2阳性原发性乳腺癌中的差异表达：与抗血管生成治疗的潜在相关性。

Differential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to anti-angiogenic therapies.

作者信息

Nasir Aejaz, Holzer Timothy R, Chen Mia, Man Michael Z, Schade Andrew E

机构信息

Diagnostic and Experimental Pathology, Eli Lilly and Company, Indianapolis, IN USA.

Eli Lilly and Company, Lilly Corporate Center, DC0424, Indianapolis, IN 46285 USA.

出版信息

Cancer Cell Int. 2017 May 19;17:56. doi: 10.1186/s12935-017-0427-5. eCollection 2017.

DOI:10.1186/s12935-017-0427-5
PMID:28533703
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5438568/
Abstract

BACKGROUND

Clinically relevant predictive biomarkers to tailor anti-angiogenic therapies to breast cancer (BRC) patient subpopulations are an unmet need.

METHODS

We analyzed tumor vascular density and VEGFR2 protein expression in various subsets of primary human BRCs (186 females; Mean age: 59 years; range 33-88 years), using a tissue microarray. Discrete VEGFR2+ and CD34+ tumor vessels were manually scored in invasive ductal, lobular, mixed ductal-lobular and colloid (N = 139, 22, 18, 7) BRC cores.

RESULTS

The observed CD34+ and VEGFR2+ tumor vascular counts in individual cases were heterogeneous. Mean CD34+ and VEGFR2+ tumor vessel counts were 11 and 3.4 per tumor TMA core respectively. Eighty-nine of 186 (48%) cases had >10 CD34+ tumor vessels, while 97/186 (52%) had fewer CD34+ vessels in each TMA core. Of 169 analyzable cores in the VEGFR2 stained TMA, 90 (53%) showed 1-5 VEGFR2+ tumor vessels/TMA core, while 42/169 (25%) cores had no detectable VEGFR2+ tumor vessels. Thirteen of 169 (8%) cases also showed tumor cell (cytoplasmic/membrane) expression of VEGFR2. Triple-negative breast cancers (TNBCs) appeared to be less vascular (Mean VD = 9.8, range 0-34) than other breast cancer subtypes. Overall, VEGFR2+ tumor vessel counts were significantly higher in HER2+ as compared to HR+ (p = 0.04) and TNBC (p = 0.02) tissues. Compared to HER2- cases, HER2+ breast cancers had higher VEGFR2+ tumor vessel counts (p = 0.007).

CONCLUSION

Characterization of pathologic angiogenesis in HER2+ breast cancer provides scientific rationale for future investigation of clinical activity of agents targeting the VEGF/VEGFR2 axis in this clinically aggressive breast cancer subtype.

摘要

背景

尚未找到可用于为乳腺癌（BRC）患者亚群量身定制抗血管生成疗法的具有临床相关性的预测生物标志物。

方法

我们使用组织微阵列分析了原发性人类BRC不同亚组（186名女性；平均年龄：59岁；范围33 - 88岁）中的肿瘤血管密度和VEGFR2蛋白表达。在浸润性导管癌、小叶癌、导管 - 小叶混合癌和黏液癌（分别为N = 139、22、18、7）的BRC样本芯中，对离散的VEGFR2 +和CD34 +肿瘤血管进行手动计数。

结果

在个别病例中观察到的CD34 +和VEGFR2 +肿瘤血管计数存在异质性。每个肿瘤组织微阵列样本芯中CD34 +和VEGFR2 +肿瘤血管的平均计数分别为11和3.4。186例中有89例（48%）每个样本芯的CD34 +肿瘤血管>10条，而186例中有97例（52%）每个样本芯的CD34 +血管较少。在VEGFR2染色的组织微阵列中，169个可分析样本芯中，90个（53%）每个样本芯显示1 - 5条VEGFR2 +肿瘤血管，而169个样本芯中有42个（25%）未检测到VEGFR2 +肿瘤血管。169例中有13例（8%）还显示肿瘤细胞（细胞质/细胞膜）表达VEGFR2。三阴性乳腺癌（TNBC）的血管似乎比其他乳腺癌亚型少（平均血管密度 = 9.8，范围0 - 34）。总体而言，与HR +（p = 0.04）和TNBC（p = 0.02）组织相比，HER2 +组织中的VEGFR2 +肿瘤血管计数显著更高。与HER2 -病例相比，HER2 +乳腺癌的VEGFR2 +肿瘤血管计数更高（p = 0.007）。

结论

HER2 +乳腺癌中病理性血管生成的特征为未来研究针对VEGF/VEGFR2轴的药物在这种临床侵袭性乳腺癌亚型中的临床活性提供了科学依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a58/5438568/03ee7cdd48d3/12935_2017_427_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a58/5438568/ebf41c0e949d/12935_2017_427_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a58/5438568/d32dcc947efd/12935_2017_427_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a58/5438568/d168e5c8be18/12935_2017_427_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a58/5438568/4e807d0a58f8/12935_2017_427_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a58/5438568/03ee7cdd48d3/12935_2017_427_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a58/5438568/ebf41c0e949d/12935_2017_427_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a58/5438568/d32dcc947efd/12935_2017_427_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a58/5438568/d168e5c8be18/12935_2017_427_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a58/5438568/4e807d0a58f8/12935_2017_427_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a58/5438568/03ee7cdd48d3/12935_2017_427_Fig5_HTML.jpg

相似文献

1
Differential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to anti-angiogenic therapies.VEGFR2蛋白在人HER2阳性原发性乳腺癌中的差异表达：与抗血管生成治疗的潜在相关性。
Cancer Cell Int. 2017 May 19;17:56. doi: 10.1186/s12935-017-0427-5. eCollection 2017.
2
Heterogeneity of Vascular Endothelial Growth Factor Receptors 1, 2, 3 in Primary Human Colorectal Carcinoma.原发性人类结直肠癌中血管内皮生长因子受体1、2、3的异质性
Anticancer Res. 2016 Jun;36(6):2683-96.
3
Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial.血管生成相关蛋白与早期乳腺癌患者特定预后因素、乳腺癌亚型和生存结局的关系。希腊肿瘤协作组（HeCOG）试验。
PLoS One. 2018 Jul 31;13(7):e0200302. doi: 10.1371/journal.pone.0200302. eCollection 2018.
4
Morphometric and immunohistochemical study of angiogenic marker expressions in invasive ductal carcinoma of human breast.人乳腺浸润性导管癌中血管生成标志物表达的形态计量学和免疫组织化学研究
Folia Morphol (Warsz). 2009 Aug;68(3):144-55.
5
A Novel Bispecific Antibody Targeting EGFR and VEGFR2 Is Effective against Triple Negative Breast Cancer via Multiple Mechanisms of Action.一种靶向表皮生长因子受体（EGFR）和血管内皮生长因子受体2（VEGFR2）的新型双特异性抗体通过多种作用机制有效对抗三阴性乳腺癌。
Cancers (Basel). 2021 Mar 1;13(5):1027. doi: 10.3390/cancers13051027.
6
Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.血管内皮生长因子受体2而非血管内皮生长因子或人表皮生长因子受体2的肿瘤特异性表达与绝经前乳腺癌辅助他莫昔芬治疗反应受损相关。
J Clin Oncol. 2005 Jul 20;23(21):4695-704. doi: 10.1200/JCO.2005.08.126.
7
Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis.原发性乳腺癌中 4q12 处 KIT 和 VEGFR2 基因拷贝数的增加与侵袭性表型和预后不良有关。
Genes Chromosomes Cancer. 2012 Apr;51(4):375-83. doi: 10.1002/gcc.21922. Epub 2011 Dec 14.
8
Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.肿瘤内异质性作为乳腺癌生物标志物分类不一致的一个来源。
Breast Cancer Res. 2016 Jun 28;18(1):68. doi: 10.1186/s13058-016-0725-1.
9
Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.使用定量氟-18氟脱氧葡萄糖/正电子发射断层扫描成像参数比较三阴性乳腺癌与雌激素受体阳性/孕激素受体阳性/人表皮生长因子受体2阴性乳腺癌：一种对疾病特征描述可能有用的方法。
Cancer. 2008 Mar 1;112(5):995-1000. doi: 10.1002/cncr.23226.
10
Expression of HIF-1α and Markers of Angiogenesis Are Not Significantly Different in Triple Negative Breast Cancer Compared to Other Breast Cancer Molecular Subtypes: Implications for Future Therapy.与其他乳腺癌分子亚型相比，三阴性乳腺癌中HIF-1α的表达和血管生成标志物无显著差异：对未来治疗的启示。
PLoS One. 2015 Jun 5;10(6):e0129356. doi: 10.1371/journal.pone.0129356. eCollection 2015.

引用本文的文献

1
RNF114 Interacts with EWSR1 to Regulate VEGFR2 in HER2-positive Breast Cancer.RNF114与EWSR1相互作用以调节HER2阳性乳腺癌中的VEGFR2。
J Cancer. 2025 Feb 28;16(6):1888-1904. doi: 10.7150/jca.106001. eCollection 2025.
2
Novel Molecular Classification of Breast Cancer with PET Imaging.基于PET成像的乳腺癌新型分子分类
Medicina (Kaunas). 2024 Dec 21;60(12):2099. doi: 10.3390/medicina60122099.
3
Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor A (VEGF-A) expressions in Ethiopian female breast cancer and their association with histopathologic features.

本文引用的文献

1
Targeting angiogenesis in gastrointestinal tumors: current challenges.靶向胃肠道肿瘤血管生成：当前挑战
Transl Gastroenterol Hepatol. 2016 Sep 6;1:67. doi: 10.21037/tgh.2016.08.04. eCollection 2016.
2
Heterogeneity of Vascular Endothelial Growth Factor Receptors 1, 2, 3 in Primary Human Colorectal Carcinoma.原发性人类结直肠癌中血管内皮生长因子受体1、2、3的异质性
Anticancer Res. 2016 Jun;36(6):2683-96.
3
CDK4/6 Inhibition Overcomes Drug Resistance in HER2+ Breast Cancer.CDK4/6 抑制克服了 HER2+乳腺癌的耐药性。
表皮生长因子受体 (EGFR) 和血管内皮生长因子 A (VEGF-A) 在埃塞俄比亚女性乳腺癌中的表达及其与组织病理学特征的关系。
PLoS One. 2024 Oct 15;19(10):e0308411. doi: 10.1371/journal.pone.0308411. eCollection 2024.
4
MUFFIN: a suite of tools for the analysis of functional sequencing data.MUFFIN：一套用于分析功能测序数据的工具。
NAR Genom Bioinform. 2024 May 14;6(2):lqae051. doi: 10.1093/nargab/lqae051. eCollection 2024 Jun.
5
Disitamab Vedotin (RC48) combined with bevacizumab for treatment of HR-negative/HER2-positive metastatic breast cancer with liver and brain involvement: A case report.迪西他单抗维泊妥珠单抗（RC48）联合贝伐单抗治疗合并肝脑转移的激素受体阴性/人表皮生长因子受体2阳性转移性乳腺癌：一例报告
Front Oncol. 2023 Aug 28;13:1245701. doi: 10.3389/fonc.2023.1245701. eCollection 2023.
6
Prognostic Significance of Microvessel Density in Invasive Ductal Carcinoma of Breast.微血管密度在乳腺浸润性导管癌中的预后意义
Int J Hematol Oncol Stem Cell Res. 2023 Apr 1;17(2):100-105. doi: 10.18502/ijhoscr.v17i2.12646.
7
Apatinib combined with trastuzumab and albumin-bound paclitaxel for treatment of HER2+ breast cancer with brain metastases resistant to anti-HER2 TKIs: A case report.阿帕替尼联合曲妥珠单抗和白蛋白结合型紫杉醇治疗对抗HER2酪氨酸激酶抑制剂耐药的HER2阳性脑转移乳腺癌：一例报告
Oncol Lett. 2022 Dec 20;25(2):56. doi: 10.3892/ol.2022.13642. eCollection 2023 Feb.
8
The reversal of anti-HER2 resistance in advanced HER2-positive breast cancer using apatinib: two cases reports and literature review.阿帕替尼用于逆转晚期HER2阳性乳腺癌抗HER2耐药性：两例报告及文献综述
Transl Cancer Res. 2022 Nov;11(11):4206-4217. doi: 10.21037/tcr-22-2483.
9
A Novel Her2/VEGFR2/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy.一种新型的具有最佳结构设计的 Her2/VEGFR2/CD3 三特异性抗体，表现出改善的 T 细胞重定向抗肿瘤疗效。
Theranostics. 2022 Nov 14;12(18):7788-7803. doi: 10.7150/thno.75037. eCollection 2022.
10
Early Imaging Findings of Hypertrophic Osteoarthropathy Mimicking Bone Metastasis from Extrathoracic Malignancy.酷似胸外恶性肿瘤骨转移的肥厚性骨关节病的早期影像学表现
Taehan Yongsang Uihakhoe Chi. 2021 Nov;82(6):1606-1612. doi: 10.3348/jksr.2020.0154. Epub 2020 Nov 23.
Cancer Discov. 2016 May;6(5):OF4. doi: 10.1158/2159-8290.CD-RW2016-054. Epub 2016 Mar 24.
4
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.克服 CDK4/6 抑制剂治疗 HER2 阳性乳腺癌的耐药性
Cancer Cell. 2016 Mar 14;29(3):255-269. doi: 10.1016/j.ccell.2016.02.006.
5
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.雷莫芦单抗联合 FOLFIRI 二线治疗用于贝伐珠单抗、奥沙利铂和氟嘧啶一线治疗后进展的转移性结直肠癌患者：一项随机、双盲、多中心、III 期研究（RAISE）。
Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12.
6
CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models.在临床前乳腺癌模型中，CDK4/6抑制为Her2靶向治疗提供了一种有效的辅助治疗方法。
Genes Cancer. 2014 Jul;5(7-8):261-72. doi: 10.18632/genesandcancer.24.
7
Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.ROSE/TRIO-12 的主要结果，这是一项随机安慰剂对照 III 期试验，评估了在转移性乳腺癌中添加雷莫芦单抗到一线多西他赛化疗中的疗效。
J Clin Oncol. 2015 Jan 10;33(2):141-8. doi: 10.1200/JCO.2014.57.1513. Epub 2014 Sep 2.
8
HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development.人表皮生长因子受体2阳性晚期乳腺癌：优化患者治疗结局及药物研发机遇
Br J Cancer. 2014 Nov 11;111(10):1888-98. doi: 10.1038/bjc.2014.388. Epub 2014 Jul 15.
9
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.雷莫芦单抗联合多西他赛对比安慰剂联合多西他赛二线治疗铂类化疗后进展的 IV 期非小细胞肺癌（REVEL）：一项多中心、双盲、随机 III 期临床试验。
Lancet. 2014 Aug 23;384(9944):665-73. doi: 10.1016/S0140-6736(14)60845-X. Epub 2014 Jun 2.
10
Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lung.肿瘤细胞中血管内皮生长因子受体2的表达是肺鳞状细胞癌患者的不良预后因素。
PLoS One. 2013 Nov 14;8(11):e80292. doi: 10.1371/journal.pone.0080292. eCollection 2013.